ArticleMolecular and clinical oncology2025
Patient background and laboratory variables associated with the efficacy of nivolumab after chemoradiotherapy in esophageal squamous cell carcinoma.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal squamous cell carcinoma (ESCC) is refractory to multidisciplinary treatment. Immunotherapy targeting programmed cell death protein 1 has shown promise in recent years; however, predicting its therapeutic efficacy remains difficult. The present study aimed to identify the factors associated with treatment response in patients receiving nivolumab after radical chemoradiotherapy for ESCC and to predict treatment efficacy based on these factors. A total of 22 patients were classified into partial response (PR) + stable disease (SD) and progressive disease (PD) groups based on their response to nivolumab. Factors associated with the treatment response were analyzed, including clinical stage, patient background and pre-treatment blood test results. Among the 22 patients, nine and 13 were classified into the PR + SD and PD groups, respectively. Notably, treatment efficacy had a significant impact on prognosis. Variables such as height, weight, body mass index, white blood cell count, basophil fraction, platelet count, albumin, creatinine and C-reactive protein were also evaluated. Cut-off values were determined using the Youden index for body weight (53.5 kg), white blood cells (5,000/mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.